Skip to content

Evan Wood

3 papers in the library · 271 citations · publishing 2015-2017

Papers

Sort Most recent Most cited

Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting

BMJ Open September 1, 2017 Elena Argento, Steffanie A. Strathdee, Kenneth W. Tupper et al. 60 citations

Objective This study aimed to longitudinally investigate whether ever having used a psychedelic drug can have a protective effect on incidence of suicidality among marginalised women. Design Longitudinal community-based cohort study. Setting Data were drawn from a prospective, community-based cohort of marginalised women in Metro Vancouver, Canada. Participants 766 women completed the baseline...

Remission of Severe Opioid Use Disorder with Ibogaine: A Case Report.

Journal of Psychoactive Drugs 2016 Laurie Cloutier-Gill, Evan Wood, Trevor Millar et al. 22 citations

Opioid use disorders (OUD) translate into major health, social, and economic consequences. Opioid agonist medications, which generally require long-term administration, are the mainstay pharmacological treatment of OUD. However, a large proportion of individuals with OUD either refuse or fail to respond to these therapies. Ibogaine, a naturally occurring substance found in the Tabernanthe iboga...

Psychedelic medicine: a re-emerging therapeutic paradigm

Canadian Medical Association Journal September 8, 2015 Kenneth W. Tupper, Evan Wood, Richard Yensen et al. 189 citations

In clinical research settings around the world, renewed investigations are taking place on the use of psychedelic substances for treating illnesses such as addiction, depression, anxiety and posttraumatic stress disorder (PTSD). Since the termination of a period of research from the 1950s to the